Transmission potential of vaccinated and unvaccinated persons infected with the SARS-CoV-2 Delta variant in a federal prison, July-August 2021.

COVID-19 transmission Correctional facilities Infectious disease outbreaks Vaccination Virus shedding

Journal

Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899

Informations de publication

Date de publication:
10 03 2023
Historique:
received: 27 09 2022
accepted: 19 11 2022
pubmed: 27 12 2022
medline: 7 3 2023
entrez: 26 12 2022
Statut: ppublish

Résumé

The extent to which vaccinated persons who become infected with SARS-CoV-2 contribute to transmission is unclear. During a SARS-CoV-2 Delta variant outbreak among incarcerated persons with high vaccination rates in a federal prison, we assessed markers of viral shedding in vaccinated and unvaccinated persons. Consenting incarcerated persons with confirmed SARS-CoV-2 infection provided mid-turbinate nasal specimens daily for 10 consecutive days and reported symptom data via questionnaire. Real-time reverse transcription-polymerase chain reaction (RT-PCR), viral whole genome sequencing, and viral culture was performed on these nasal specimens. Duration of RT-PCR positivity and viral culture positivity was assessed using survival analysis. A total of 957 specimens were provided by 93 participants, of whom 78 (84 %) were vaccinated and 17 (16 %) were unvaccinated. No significant differences were detected in duration of RT-PCR positivity among vaccinated participants (median: 13 days) versus those unvaccinated (median: 13 days; p = 0.50), or in duration of culture positivity (medians: 5 days and 5 days; p = 0.29). Among vaccinated participants, overall duration of culture positivity was shorter among Moderna vaccine recipients versus Pfizer (p = 0.048) or Janssen (p = 0.003) vaccine recipients. In post-hoc analyses, Moderna vaccine recipients demonstrated significantly shorter duration of culture positivity compared to unvaccinated participants (p = 0.02). When restricted to participants without reported prior infection, the difference between Moderna vaccine recipients and unvaccinated participants was more pronounced (medians: 3 days and 6 days, p = 0.002). Infectious periods for vaccinated and unvaccinated persons who become infected with SARS-CoV-2 are similar and can be highly variable, though some vaccinated persons are likely infectious for shorter durations. These findings are critically important, especially in congregate settings where viral transmission can lead to large outbreaks. In such settings, clinicians and public health practitioners should consider vaccinated, infected persons to be no less infectious than unvaccinated, infected persons.

Sections du résumé

BACKGROUND
The extent to which vaccinated persons who become infected with SARS-CoV-2 contribute to transmission is unclear. During a SARS-CoV-2 Delta variant outbreak among incarcerated persons with high vaccination rates in a federal prison, we assessed markers of viral shedding in vaccinated and unvaccinated persons.
METHODS
Consenting incarcerated persons with confirmed SARS-CoV-2 infection provided mid-turbinate nasal specimens daily for 10 consecutive days and reported symptom data via questionnaire. Real-time reverse transcription-polymerase chain reaction (RT-PCR), viral whole genome sequencing, and viral culture was performed on these nasal specimens. Duration of RT-PCR positivity and viral culture positivity was assessed using survival analysis.
RESULTS
A total of 957 specimens were provided by 93 participants, of whom 78 (84 %) were vaccinated and 17 (16 %) were unvaccinated. No significant differences were detected in duration of RT-PCR positivity among vaccinated participants (median: 13 days) versus those unvaccinated (median: 13 days; p = 0.50), or in duration of culture positivity (medians: 5 days and 5 days; p = 0.29). Among vaccinated participants, overall duration of culture positivity was shorter among Moderna vaccine recipients versus Pfizer (p = 0.048) or Janssen (p = 0.003) vaccine recipients. In post-hoc analyses, Moderna vaccine recipients demonstrated significantly shorter duration of culture positivity compared to unvaccinated participants (p = 0.02). When restricted to participants without reported prior infection, the difference between Moderna vaccine recipients and unvaccinated participants was more pronounced (medians: 3 days and 6 days, p = 0.002).
CONCLUSIONS
Infectious periods for vaccinated and unvaccinated persons who become infected with SARS-CoV-2 are similar and can be highly variable, though some vaccinated persons are likely infectious for shorter durations. These findings are critically important, especially in congregate settings where viral transmission can lead to large outbreaks. In such settings, clinicians and public health practitioners should consider vaccinated, infected persons to be no less infectious than unvaccinated, infected persons.

Identifiants

pubmed: 36572604
pii: S0264-410X(22)01458-X
doi: 10.1016/j.vaccine.2022.11.045
pmc: PMC9744684
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1808-1818

Informations de copyright

Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

Lancet Infect Dis. 2022 Feb;22(2):183-195
pubmed: 34756186
MMWR Morb Mortal Wkly Rep. 2021 Sep 24;70(38):1349-1354
pubmed: 34555009
MMWR Morb Mortal Wkly Rep. 2020 Aug 21;69(33):1139-1143
pubmed: 32817597
PLoS Pathog. 2022 Sep 30;18(9):e1010876
pubmed: 36178969
Open Forum Infect Dis. 2022 Apr 13;9(7):ofac192
pubmed: 35791353
Emerg Infect Dis. 2020 Jun;26(6):1266-1273
pubmed: 32160149
MMWR Morb Mortal Wkly Rep. 2021 Aug 06;70(31):1059-1062
pubmed: 34351882
MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1170-1176
pubmed: 34437525
Clin Infect Dis. 2021 Sep 15;73(6):e1348-e1355
pubmed: 33846714
Clin Infect Dis. 2022 Oct 3;75(Suppl 2):S159-S166
pubmed: 35675695
J Stat Softw. 2010 Aug;36(2):
pubmed: 25285054
Nat Med. 2021 Dec;27(12):2127-2135
pubmed: 34650248
Clin Microbiol Infect. 2022 Apr;28(4):612.e1-612.e7
pubmed: 34826623
MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):339-342
pubmed: 32214083
Am J Pathol. 2022 Feb;192(2):320-331
pubmed: 34774517
Nat Microbiol. 2022 May;7(5):640-652
pubmed: 35484231
Clin Infect Dis. 2022 Aug 24;75(1):e715-e725
pubmed: 34922338
Infect Dis Model. 2021;6:1110-1134
pubmed: 34518808

Auteurs

Phillip P Salvatore (PP)

COVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States; United States Public Health Service, Rockville, MD, United States. Electronic address: pgx5@cdc.gov.

Christine C Lee (CC)

COVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States; Laboratory Leadership Service, Centers for Disease Control and Prevention, Atlanta, GA, United States.

Sadia Sleweon (S)

COVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States.

David W McCormick (DW)

COVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States; United States Public Health Service, Rockville, MD, United States; Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA, United States.

Lavinia Nicolae (L)

COVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States.

Kristen Knipe (K)

COVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States.

Tom Dixon (T)

Bureau of Prisons, U.S. Department of Justice, Washington, DC, United States.

Robert Banta (R)

United States Public Health Service, Rockville, MD, United States; Bureau of Prisons, U.S. Department of Justice, Washington, DC, United States.

Isaac Ogle (I)

United States Public Health Service, Rockville, MD, United States; Bureau of Prisons, U.S. Department of Justice, Washington, DC, United States.

Cristen Young (C)

Bureau of Prisons, U.S. Department of Justice, Washington, DC, United States.

Charles Dusseau (C)

United States Public Health Service, Rockville, MD, United States; Bureau of Prisons, U.S. Department of Justice, Washington, DC, United States.

Shawn Salmonson (S)

Bureau of Prisons, U.S. Department of Justice, Washington, DC, United States.

Charles Ogden (C)

United States Public Health Service, Rockville, MD, United States; Bureau of Prisons, U.S. Department of Justice, Washington, DC, United States.

Eric Godwin (E)

Bureau of Prisons, U.S. Department of Justice, Washington, DC, United States.

TeCora Ballom (T)

United States Public Health Service, Rockville, MD, United States; Bureau of Prisons, U.S. Department of Justice, Washington, DC, United States.

Tara Rhodes (T)

United States Public Health Service, Rockville, MD, United States; Bureau of Prisons, U.S. Department of Justice, Washington, DC, United States.

Nhien Tran Wynn (NT)

COVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States.

Ebenezer David (E)

COVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States.

Theresa K Bessey (TK)

COVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States.

Gimin Kim (G)

COVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States.

Suganthi Suppiah (S)

COVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States.

Azaibi Tamin (A)

COVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States.

Jennifer L Harcourt (JL)

COVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States.

Mili Sheth (M)

COVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States.

Luis Lowe (L)

COVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States.

Hannah Browne (H)

COVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States.

Jacqueline E Tate (JE)

COVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States; United States Public Health Service, Rockville, MD, United States.

Hannah L Kirking (HL)

COVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States; United States Public Health Service, Rockville, MD, United States.

Liesl M Hagan (LM)

COVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH